SCHEMBL989596

SCHEMBL989596

O=C(O)c1ccccc1P(c1ccccc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
ALOX15 P16050 1/20 0.54
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA4 P22748 3/20 0.46
CA7 P43166 3/20 0.46
CA9 Q16790 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HMGB1 P09429 2/20 0.46
HPGD P15428 2/20 0.46
NAPRT Q6XQN6 2/20 0.46
CA6 P23280 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CA14 Q9ULX7 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 2/20 0.45
HDAC8 Q9BY41 1/20 0.45
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404318 1.00 ALDH1A1 (0.54) ALDH1A1ALOX15CA12CA1CA2
Phosphine SCHEMBL22446073 0.98 ALDH1A1 (0.52) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL5597248 0.98 ALDH1A1 (0.52) ALDH1A1ALOX15CA12CA1CA2
Bromide SCHEMBL3660816 0.98 ALDH1A1 (0.52) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL31553567 0.98 ALDH1A1 (0.52) ALDH1A1ALOX15CA12CA1CA2
Ammonia Solution, Strong SCHEMBL31339444 0.98 ALDH1A1 (0.52) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL7564286 0.96 ALDH1A1 (0.54) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL31003867 0.92 ALDH1A1 (0.46) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL7260802 0.89 ALDH1A1 (0.62) ALDH1A1ALOX15CA12CA1CA2
SCHEMBL1524729 0.87 CYP3A4 (0.46) ALDH1A1ALOX15CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 809 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612343-B2 PSMA binder and use thereof Shiya Pharmaceutical, Inc (CN) 2026-04-28 US claimed
WO-2025106936-A1 POLY(METH)ACRYLIMIDE MATERIALS WITH ENHANCED THERMOMECHANICAL PROPERTIES GENCORES, INC. (US) 2025-05-22 WO claimed
CN-115372341-B Bioluminescence detection system of bacterial cell wall neopeptidoglycan constructed by D-lysine derivative and application method 西北工业大学深圳研究院 2025-04-25 CN claimed
CN-119874466-A N, N-dimethylamide compound and synthesis method thereof 海南大学 2025-04-25 CN claimed
US-20250122269-A1 SELECTIVE REDUCTION OF ANTIBODIES ABBVIE INC (US) 2025-04-17 US claimed
US-20250073692-A1 PROCESS FOR PREPARING LINEAR ALPHA-OLEFIN BY OLIGOMERIZATION OF ETHYLENE NANJING CHEMISTRY NEW ENERGY TECHNOLOGY CO., LTD. (CN) 2025-03-06 US claimed
CN-119488608-A Engineering bispecific antibody coupling drug and preparation method and application thereof 上海药明合联生物技术有限公司 2025-02-21 CN claimed
CN-118927721-A Breathable garment fabric and preparation method thereof 雄县广宇服装有限公司 2024-11-12 CN claimed
CN-118359573-A Coumarin-based endoplasmic reticulum targeting fluorescent probe for detecting nitrosyl hydrogen and preparation method and application thereof 南京林业大学 2024-07-19 CN claimed
US-20240216521-A1 METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES IMMUNOGEN INC (US) 2024-07-04 US claimed
US-6184428-B1 USING A SUPPORTED HETEROGENOUS CATALYST (2-DIPHENYLPHOSPHINO-BENZOIC ACID, NICKEL CHLORIDE HYDRATE AND SODIUM TETRAPHENYL-BORATE) SLURRY; CONTINUOUS PROCESSING; HIGHLY ACTIVE TO PRODUCE ALPHA-OLEFINS OF NARROW MOLECULAR WEIGHT DISTRIBUTION SAUDI BASIC INDUSTRIES CORPORATION (SA) 2001-02-06 US claimed
US-6180831-B1 REACTING 1,2-OXIRANES WITH CARBON MONOXIDE AND HYDROGEN IN PRESENCE OF COBALT TRANSITION METAL COMPOUND CATALYST, WHEREIN SAID COBALT TRANSITION METAL COMPOUND IS MODIFIED WITH PHOSPHORUS-OXYGEN LIGAND OR NITROGEN-OXYGEN LIGAND DEGUSSA-HULS AG (DE) 2001-01-30 US claimed
EP-1066298-A1 PREPARATION OF PHOSPHINE LIGANDS Chirotech Technology Limited (GB) 2001-01-10 EP claimed
WO-1999051614-A1 PREPARATION OF PHOSPHINE LIGANDS CHIROTECH TECHNOLOGY LIMITED (GB) 1999-10-14 WO claimed
EP-0177999-B1 ETHYLENE OLIGOMERIZATION PROCESS CARRIED OUT IN A DIOL-BASED SOLVENT CONTAINING MONOHYDRIC ALCOHOL OR WATER SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1989-01-18 EP claimed
EP-0177999-A1 Ethylene oligomerization process carried out in a diol-based solvent containing monohydric alcohol or water SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1986-04-16 EP claimed
US-4528416-A Ethylene oligomerization process carried out in a monohydric/dihydric alcohol solvent mixture SHELL OIL COMPANY (US) 1985-07-09 US claimed
EP-0033553-B1 NICKEL COMPLEXES IN DIOL SOLVENTS AND THEIR USE AS PART OF A CATALYST IN THE OLIGOMERIZATION OF ETHYLENE SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1984-06-06 EP claimed
EP-0033553-A2 Nickel complexes in diol solvents and their use as part of a catalyst in the oligomerization of ethylene SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1981-08-12 EP claimed
US-4260844-A Nickel complexes in diol solvents and their use as oligomerization catalyst precursors SHELL OIL COMPANY (US) 1981-04-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122269-A1 SELECTIVE REDUCTION OF ANTIBODIES CD2BP2, CD22, CD2 ALDH1A1 1260/4885ALOX15 4404/4885CA12 307/4885
US-20240216521-A1 METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES EPCAM, CD2BP2, XPA ALDH1A1 1529/4885ALOX15 3288/4885CA12 155/4885
US-12612343-B2 PSMA binder and use thereof KLK3, AR, PSMA1 ALDH1A1 524/4885ALOX15 4736/4885CA12 46/4885
US-20250073692-A1 PROCESS FOR PREPARING LINEAR ALPHA-OLEFIN BY OLIGOMERIZATION OF ETHYLENE EDF1, ELL, EEF1D ALDH1A1 3709/4885ALOX15 464/4885CA12 3943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.